NCT03372317 Tau PET in Imaging and Cognition: Healthy Adults From 55-90
| NCT ID | NCT03372317 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yaakov Stern |
| Condition | Mild Cognitive Impairment |
| Study Type | OBSERVATIONAL |
| Enrollment | 105 participants |
| Start Date | 2018-06-01 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 105 participants in total. It began in 2018-06-01 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Eligibility Criteria
Inclusion Criteria: * Aged 55-90 * Previously received an amyloid PET scan * Residing near Columbia University Medical Center * Must be willing and able to participate Exclusion Criteria: * Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour) * Pregnancy * Lactating Women * Current, past, or anticipated exposure to radiation * Significant active physical illness
Contact & Investigator
Yaakov Stern, PhD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT03372317 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 90 Years, studying Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03372317 currently recruiting?
Yes, NCT03372317 is actively recruiting participants. Contact the research team at rb2996@cumc.columbia.edu for enrollment information.
Where is the NCT03372317 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT03372317 clinical trial?
NCT03372317 is sponsored by Yaakov Stern. The principal investigator is Yaakov Stern, PhD at Columbia University. The trial plans to enroll 105 participants.